Regional Variations in Medication Usage for Cardiovascular Diseases at the Community Level in China （PURE-China Study）

We investigated the usage of secondary prevention drugs and traditional Chinese medicine （TCM） products in individuals with cardiovascular diseases （CVDs） at the community level in China. Among 2,407 participants with self-reported coronary heart disease （CHD） and 872 with stroke, nearly 80% of indi...

Full description

Saved in:
Bibliographic Details
Published in生物医学与环境科学：英文版 Vol. 30; no. 6; pp. 450 - 454
Main Author YANG Jin Gang, GU Hong Qiu BO Jian WANG Yang LI Wei
Format Journal Article
LanguageEnglish
Published 2017
Subjects
CVDs
中国西部
中药产品
城市地区
心血管疾病
用药
社会
预防药物
Online AccessGet full text

Cover

More Information
Summary:We investigated the usage of secondary prevention drugs and traditional Chinese medicine （TCM） products in individuals with cardiovascular diseases （CVDs） at the community level in China. Among 2,407 participants with self-reported coronary heart disease （CHD） and 872 with stroke, nearly 80% of individuals with CHD and 73% of individuals with stroke were not taking any proven secondary prevention drug. However, 32.9% of them took TCM products. Patients with CVDs in rural areas used less secondary prevention treatment, but more TCM products than their counterparts in the urban regions. After adjusting for confounding factors, lower rates of secondary prevention treatment were evident in Western China compared with Eastern China, which was more developed. Systematic change is needed to promote the development of evidence-based medicine at the community level in China.
Bibliography:11-2816/Q
We investigated the usage of secondary prevention drugs and traditional Chinese medicine （TCM） products in individuals with cardiovascular diseases （CVDs） at the community level in China. Among 2,407 participants with self-reported coronary heart disease （CHD） and 872 with stroke, nearly 80% of individuals with CHD and 73% of individuals with stroke were not taking any proven secondary prevention drug. However, 32.9% of them took TCM products. Patients with CVDs in rural areas used less secondary prevention treatment, but more TCM products than their counterparts in the urban regions. After adjusting for confounding factors, lower rates of secondary prevention treatment were evident in Western China compared with Eastern China, which was more developed. Systematic change is needed to promote the development of evidence-based medicine at the community level in China.
ISSN:0895-3988
2214-0190